Pharmaco - Press Releases

Date	Title	Company
03-Feb-2022	DNA Script Joins Wellcome Leap R3 Program to Advance RNA Products and Therapies	DNA Script
03-Feb-2022	UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents	Lilly
03-Feb-2022	Australians With One Of The Most Agressive Forms Of Blood Cancer Have New PBS Listed Treatment Option	AstraZeneca
03-Feb-2022	iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development	iOmx Therapeutics AG
03-Feb-2022	Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program	Biophytis
03-Feb-2022	Parkinson’s UK and Domainex collaborate to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s	Sciad Newswire
03-Feb-2022	Kuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications	Kuros Biosciences AG
03-Feb-2022	Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)	Takeda Pharmaceutical Company Limited
02-Feb-2022	Reaction Biology Announces Integrated Drug Discovery Solutions: The Reaction Oncology Platform	B3C newswire
02-Feb-2022	EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR® 2021	EISAI
02-Feb-2022	Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock	RELIEF THERAPEUTICS Holding AG
01-Feb-2022	Listing and first trading day on the 'Sparks' segment of SIX Swiss Exchange expected for February 11, 2022	Xlife Sciences AG
01-Feb-2022	BRAIN Group significantly expands its food enzyme business with the acquisition of Breatec B.V. and Comix business	BRAIN Biotech AG
01-Feb-2022	BRAIN Biotech AG: BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix	BRAIN Biotech AG
01-Feb-2022	Coriolis Pharma Opens New ATMP Formulation Development Facilities	B3C newswire
01-Feb-2022	Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine	Novavax
01-Feb-2022	Navigo Proteins Appoints Chris-Carol Bremer as Chief Development Officer	B3C newswire
01-Feb-2022	BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology	B3C newswire
01-Feb-2022	Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease	RELIEF THERAPEUTICS Holding AG
31-Jan-2022	Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development	AlivaMab Discovery Services